Grail (GRAL) Shares Surge 13.53% Amid 2026 Optimism
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Fool
- Stock Surge: Grail's shares rose over 13% to $13.68 by this afternoon, reflecting investor optimism about the company's 2026 prospects, particularly following an upbeat presentation at the JPMorgan Healthcare Conference.
- Revenue Guidance: Management projects total revenue for 2025 to be between $147 million and $148 million, with the Galleri test expected to contribute $136 million to $137 million, indicating strong market performance and growth potential.
- Cash Burn Management: Grail's cash burn is projected to decrease to $274 million in 2025 from $579 million in 2024, and with a cash position of $904 million, the company is well-positioned to operate until 2030, boosting investor confidence.
- FDA Submission Plans: Grail plans to submit a Premarket Approval (PMA) application to the FDA in Q1, which, if approved, would provide medical and insurance coverage for the Galleri test, facilitating marketing efforts and physician adoption, thereby enhancing the company's market position.
Analyst Views on GRAL
Wall Street analysts forecast GRAL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRAL is 60.86 USD with a low forecast of 38.00 USD and a high forecast of 83.71 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 101.070
Low
38.00
Averages
60.86
High
83.71
Current: 101.070
Low
38.00
Averages
60.86
High
83.71
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
